{
    "clinical_study": {
        "@rank": "89092", 
        "arm_group": [
            {
                "arm_group_label": "Bupivacaine 0.25%", 
                "arm_group_type": "Active Comparator", 
                "description": "20 cc of bupivacaine 0.25%"
            }, 
            {
                "arm_group_label": "Liposomal bupivacaine", 
                "arm_group_type": "Experimental", 
                "description": "liposomal bupivacaine (EXPAREL\u00ae; 88 mg in 20 cc)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the quality and duration of pain relief after\n      shoulder surgery provided by a single injection of liposomal bupivacaine versus standard\n      bupivacaine when administered as an interscalene brachial plexus block. It is hypothesized\n      that the liposomal bupivacaine formulation will provide more effective pain relief than\n      standard bupivacaine."
        }, 
        "brief_title": "Efficacy of Interscalene Brachial Plexus Block With Liposomal Bupivacaine for Arthroscopic Shoulder Surgery", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Shoulder Pain", 
            "Rotator Cuff Tear"
        ], 
        "condition_browse": {
            "mesh_term": "Shoulder Pain"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  English speaking adults (age >17 years) of American Society of Anesthesiologists\n             (ASA) I-III physical class scheduled for elective arthroscopic shoulder surgery will\n             be eligible to participate regardless of race/ethnicity.\n\n        Exclusion Criteria:\n\n          -  Subjects will not be eligible for this trial if they report a history of an allergy\n             to a local anesthetic, baseline neurological deficit, a medical condition that would\n             make it difficult to assess sensory distribution or communicate with the staff, a\n             recent history (< 3 months) of drug or alcohol abuse, concomitant opioid therapy, or\n             a preexisting coagulation disorder."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "17 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977352", 
            "org_study_id": "13-0064"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bupivacaine 0.25%", 
                "description": "liposomal bupivacaine (EXPAREL\u00ae; 88 mg in 20 cc)", 
                "intervention_name": "Liposomal bupivacaine", 
                "intervention_type": "Drug", 
                "other_name": "Exparel"
            }, 
            {
                "arm_group_label": "Liposomal bupivacaine", 
                "description": "20 cc of bupivacaine 0.25%", 
                "intervention_name": "Bupivacaine 0.25%", 
                "intervention_type": "Drug", 
                "other_name": "Bupivacaine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bupivacaine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Exparel", 
            "Liposomal Bupivacaine", 
            "Arthroscopic Shoulder Surgery"
        ], 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "alishariatmd@gmail.com", 
                "last_name": "Ali Shariat, MD", 
                "phone": "914-409-5023"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10025"
                }, 
                "name": "St. Luke's Roosevelt Hospital Center"
            }, 
            "investigator": {
                "last_name": "Ali Shariat, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Cumulative Opioid Consumption After Interscalene Brachial Plexus Block With Liposomal Bupivacaine (Exparel; 88 mg in 20 cc) Versus Bupivacaine 0.25% for Arthroscopic Shoulder Surgery", 
        "overall_contact": {
            "email": "alishariatmd@gmail.com", 
            "last_name": "Ali Shariat, MD", 
            "phone": "914-409-5023"
        }, 
        "overall_official": {
            "affiliation": "St. Luke's-Roosevelt Hospital Center", 
            "last_name": "Ali Shariat, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Compare total opioid consumption up to 72 hours post operatively between patients receiving bupivacaine 0.25% (20 cc) and liposomal bupivacaine (EXPAREL\u00ae; 88 mg in 20 cc) for interscalene brachial plexus block.", 
            "measure": "Total opioid consumption", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977352"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Quality of analgesia as measured by numerical rating scores (NRS-11) at 24, 48, 72 hours and 1 week postoperatively", 
                "measure": "Quality of analgesia", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }, 
            {
                "description": "Measurement of brachial plexus blockade will be carried out every 5 min up to 30 minutes upon completion of the peripheral nerve block and prior to surgery. Sensory block will be assessed by pinprick with a paper clip using a 0-2 scale: 0, no block (complete sensation); 1, parasthesia (light touch); 2, anesthesia (no sensation). Evaluation of sensory block will also be undertaken at one and two hours after arrival to the Post Anesthesia Care Unit (PACU). The first occurrence of pain perceived by the patient will be used as a surrogate for return of the sensory function.", 
                "measure": "Onset and duration of sensory block", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Time to first pain medicine", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Time to discharge home", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Incidence of postoperative nausea and vomiting", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }
        ], 
        "source": "St. Luke's-Roosevelt Hospital Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Luke's-Roosevelt Hospital Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}